CORRECTION OF CARBOHYD-RATE DISORDERS IN PATIENTS WITH PARANOID SCHIZO-PHRENIA, RECEIVING LONG-THERM THERAPY WITH NEUROLYPTICS BY METFORMIN GYDROCHLORIDE

Our goal was to investigate the early clinical and paraclinical criteria for the incidence of carbohydrate metabolism and the development of concomitant metabolic syndrome in patients with paranoid schizophrenia, who receive long-therm antipsychotics therapy and corrected these changes with metformin hydrochloride. As a result of our study, in 52% of all subjects, found a violation of carbohydrate metabolism and appointed corrective therapy with metformin hydrochloride in a dose from 500 to 1000 mg/day. As a result of our research, we found out that in all groups of examined patients a positive dynamics of carbohydrate metabolism under the influence of this drug was found. The significantly higher therapeutic effect of metformin has been shown in patients receiving the latter in combination with haloperidol. The combination of metformin with risperidone and quetiapine showed a slightly lower clinical effect. The obtained own clinical experience gives grounds to recommend metformin hydrochloride as a means of correction of the carbohydrate metabolism disorder in patients with paranoid form of schizophrenia in the process of treating this category of patients with neuroleptics.